Search results
Results From The WOW.Com Content Network
Cellular immunity, also known as cell-mediated immunity, is an immune response that does not rely on the production of antibodies. Rather, cell-mediated immunity is the activation of phagocytes , antigen-specific cytotoxic T-lymphocytes , and the release of various cytokines in response to an antigen .
The "recesive tolerance" means that the antigen is tolerated via deletion of those T cells that would facilitate immune response against the antigen (deletion of autoreactive cells in negative selection). The "dominant tolerance" means that the T cell clones specific for the antigen are deviated into Treg cells and therefore suppress the immune ...
Acute cellular rejection occurs when the recipient's T lymphocytes are activated by the donor tissue, causing damage via mechanisms such as direct cytotoxicity from CD8 cells. Acute humoral rejection and chronic disfunction occurs when the recipient's anti-HLA antibodies form directed at HLA molecules present on endothelial cells of the ...
Transplant glomerulopathy is considered a form of chronic antibody-mediated rejection. PAS stain. Chronic rejection is an insidious form of rejection that leads to graft destruction over the course of months, but most often years after tissue transplantation. [12]
Positive selection is based on steady cross-talk between T FH cells and their cognate antigen presenting GC B cell. Because a limited number of T FH cells reside in the germinal center, only highly competitive B cells stably conjugate with T FH cells and thus receive T cell-dependent survival signals. B cell progeny that have undergone SHM, but ...
These antibodies can cause antibody-mediated rejection and are therefore considered a contraindication against transplantation in most cases. [1] DSA are a result of B cell and plasma cell activation and bind to HLA and/or non-HLA molecules on the endothelium [ 1 ] of the graft.
The injection of Treg cells specific for a tumor antigen also can reverse experimentally-mediated tumor rejection based on that same antigen. [47] The prior existence of immune tolerance mechanisms due to selection for its fitness benefits facilitates its utilization in tumor growth.
Complement-dependent cytotoxicity (CDC) is an effector function of IgG and IgM antibodies.When they are bound to surface antigen on target cell (e.g. bacterial or viral infected cell), the classical complement pathway is triggered by bonding protein C1q to these antibodies, resulting in formation of a membrane attack complex (MAC) and target cell lysis.